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Developing effective anti-malarial vaccine has been a challenge for long. Various factors
including complex life cycle of parasite and lack of knowledge of stage specific critical
antigens are some of the reasons. Moreover, inadequate understanding of the immune
responses vis-à-vis sterile protection induced naturally by Plasmodia infection has further
compounded the problem. It has been shown that people living in endemic areas take years
to develop protective immunity to blood stage infection. But hardly anyone believes that
immunity to liver-stage infection could be developed. Various experimental model studies
using attenuated parasite suggest that liver-stage immunity might exist among endemic
populations.This could be induced because of the attenuation of parasite in liver by various
compounds present in the diet of endemic populations.
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INTRODUCTION
Malaria along with HIV and TB poses great challenge to human
health. More than 200 million people are at high risk and millions
are dying (particularly, children) every year across the globe (1).
Although anti-malarial drugs have helped bring down the sever-
ity and mortality of malaria in endemic regions, emergence of
drug resistant parasite poses a great challenge to the human health
prompting the urgent need for vaccine(s). Developing effective
vaccines, however, has been challenging because of the complex life
cycle of Plasmodia, which starts with the asymptomatic liver stage
followed by the symptomatic blood stage infection (Figure 1).
Various studies have shown the generation of protective immu-
nity against the blood stage infection after repeated exposure to
the parasite (2), but it is questionable against the liver stage (3, 4).
However, experiments, using radiation or genetically attenuated
sporozoite (RAS or GAS) that fails to complete their developmen-
tal cycle in liver, demonstrate the induction of sterile immunity in
rodents and humans (2, 5–7). Even chemoprophylaxis and sporo-
zoite (CPS) immunization that kills the parasite at early stage in
RBCs (restricting its development to the liver) has shown similar
results (2, 5, 7, 8). Although humoral and cell mediated responses
are required to develop protection, CD8+ T cell response, gener-
ated by attenuated parasite, seems to play a critical role in providing
protracted protection at liver stage (2, 3, 5–8). These findings
prompted us to think that there is possibility of inducing liver-
stage specific immune responses in humans by the parasite that
might be attenuated or restricted to liver during natural infection.
People living in different subcontinents with high endemicity
for malaria have been shown to have varying degree of susceptibil-
ity to infection (Table 1) (1). It becomes difficult to protect the host
if the parasite enters the blood stage without being interrupted
at liver stage as parasite load in blood could be uncontrollably
high. Therefore, restricting the parasite to the liver could generate
the protective immunity against malaria indicating the differential
susceptibility of endemic people to challenge. Food habits have
been shown to have a major impact on the health and modulation
of immune response. For example, in India, people consume many
herbs/spices as a part of their daily diet, which has been shown to
have an anti-malarial activity, as explained later. This article has
made an attempt to explain how parasites could be attenuated or
restricted “naturally” to either liver stage or blood stage by the
diet of people living in malaria endemic areas, potentially helping
generate liver-stage specific immune responses.
CHALLENGES IN MALARIA VACCINE DEVELOPMENT
Sterile protection to malaria even in endemic populations is not
yet fully understood. Even vaccination has failed to induce the
desired protection because of involvement of many complex fac-
tors (9–16). However, researchers have designed strategies that
could provide sterile protection. Both blood and liver vaccina-
tion strategies are under different phases of clinical trials (17).
The majority of the efforts to understand the immune response
against Plasmodia infection in humans are directed against blood
stage infection. But none of the blood stage vaccine candidates
that have been tried so far demonstrated appreciable efficacy (18,
19). The same is also true for the liver-stage subunit vaccine candi-
dates (20). Moreover, unlike the rationale of choosing blood stage
vaccine candidates, the antigens for liver-stage vaccines have not
been selected based on the understanding of protective immune
response in humans against liver-stage infection, a probable reason
for not having the right liver stage antigenic target. RAS, GAS, and
CPS have shown appreciable efficacy (2, 5–8). Despite promising
results, these approaches might not be feasible to adopt for mass
vaccination. Considering the world population at risk of malaria,
the feasibility of making billions of doses and maintaining the
quality are very challenging. Second, GAS has been shown to revert
to infectious parasite (21, 22) posing a threat to people expected
to take vaccine for prophylaxis. Although CPS immunization is an
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FIGURE 1 | Life cycle of Plasmodium falciparum. The life cycle of parasite
P. falciparum starts in human with inoculation of parasite through mosquito.
From the site of injection, sporozoite (SPZ) reaches to the liver and infect
hepatocytes. The SPZ multiplies and produces thousands of blood stage
infective merozoites. These merozoites enter the blood stream and infect the
RBCs to start the erythrocytic cycle of parasite. In RBC, they go through
different stages of development before they release the merozoites to infect
new RBCs. A small percentage of asexual parasite transforms into sexual
form, i.e., gametocytes, which finally develop into sporozoites in the
mosquitoes.
attractive vaccination approach, drug resistant parasites and side
effects of drug possess challenges. Therefore, approaches like a sub-
unit vaccine will be good alternative. Inducing sterile protection
by subunit vaccines requires identification of the right antigenic
targets. From the experience of LSA-1 as vaccine candidate, it is
critical to have new targets that would induce humoral and T cell
responses. Unless we understand the nature of immune response
vis-à-vis protection that exists in endemic population, it will be
difficult to identify the targets. Because of the lack of knowledge
of liver-stage specific immune responses among endemic popula-
tions, it is strongly believed that protective immunity to liver stage
does not exist; hence efforts to make a liver-stage vaccine have
not been prioritized, a reason in our opinion, for not having an
effective vaccine against malaria even decades after the trial of RAS
vaccination.
EXISTENCE OF NATURAL IMMUNITY TO LIVER STAGE
Many factors including genetic diversity, environmental condi-
tions, and mosquito species do contribute to the differential sus-
ceptibility to infection (23–25). While this is true for most of the
people living in different parts of the world, we strongly feel that
the gain of such differential protection could have a direct correla-
tion with the ability of endemic populations to generate liver-stage
specific immune responses. Even though there is blood stage spe-
cific protective immunity in people in malaria endemic areas (2),
often they come down with the infection (3). It indicates that pro-
tective immunity against the blood stage might not be sufficient,
and therefore, liver-stage immunity is required to eliminate the
parasite. Experiments suggest that achieving protective immunity
requires both CD8+ T cells and antibody response (26) because
CD8+ T cells are essential for liver-stage parasite while humoral
response is key to control blood stage (27). Although fewer studies
have been done in endemic populations, there is clear indication
that immune responses to liver stage leading to protection could
be achievable. In support of this, the studies conducted by the
research groups of Marc Connelly and Adrian Hill in Africa have
shown that protection, although among a minute endemic popula-
tion, correlates with immune response to liver-stage antigen (LSA)
(23, 28, 29). As discussed before, immunization with attenuated
or drug restricted Plasmodium falciparum sporozoite is very effec-
tive in both animal models and in humans. Results indicate that
protection is achievable either by vaccinating the host or exposing
the host to the parasite attenuated or restricted naturally.
ENDEMICITY VS. INFECTIVITY AMONG ENDEMIC
POPULATIONS
Our analysis of WHO data shows that people of certain subconti-
nents are less susceptible to malaria than others having similar risk
of high endemicity (Table 1). People living in Indian subcontinents
have been showing lower incidence of malaria compared to other
countries having endemicity either lower or higher than India.
India is having 0.48% malaria incidence,which is seven times lower
than that of Madagascar, i.e., 3.50%. Malarial endemicity of India
is 22% while that of Madagascar is 30% (Table 1). Various states
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Table 1 | List of countries with their UnionTerritory population, malaria endemic population, malaria confirmed cases, percent population at
high risk, and percent incidence of malaria in 2011.
Country (A) UN population (B) Population at
high risk
(C) Population at high
risk (%) (B×100)/A
(D) Malaria confirmed
cases
(E) Incidence of malaria (%)
(D×100)/B
China 1,347,565,324 191,908 0.014 4498 2.34
Brazil 196,655,014 4,523,065 2.3 267,045 5.9
Nepal 30, 485, 798 1, 127, 975 3.7 71, 752 6.36
South Africa 50, 459, 978 2, 018, 399 4 9866 0.49
Thailand 69, 518, 555 5, 561, 484 8 24, 897 0.45
India 1,241,491,960 273,128,231 22 1,310,367 0.48
Madagascar 21,315,135 6,394,541 30 224,498 3.51
Myanmar 48, 336, 763 17, 884, 602 37 567, 452 3.17
Timor-Leste 1, 153, 834 888, 452 76.99 36, 064 4.06
Mali 15, 839, 538 14, 255, 584 89.99 1, 293, 547 9.07
Papua New Guinea 7, 013, 829 6, 592, 999 94 1, 025, 082 15.55
Vanuatu 245, 619 243, 163 99 5764 2.37
Solomon Islands 552, 267 546, 744 99 80, 859 14.79
Nigeria 162, 470, 737 162, 470, 737 100 3, 392, 234 2.09
Angola 19, 618, 432 19, 618, 432 100 2, 534, 549 12.92
Ghana 24, 965, 816 24, 965, 816 100 3, 240, 791 12.98
Zambia 13, 474, 959 13, 474, 959 100 4, 607, 908 34.19
of India, e.g., Arunachal Pradesh, Meghalaya, Mizoram, Tripura,
Jharkhand, and Odisha are having high risk (72–100%) of infec-
tion (Table 2) (30), but the rate of malaria infection is about 0.72%.
In contrast, China and Brazil where only 0.014–2.3% population
at high risk but incidence of malaria is 2.3–5.9%, which is three-
fold to eightfold higher than that of India (Table 1), based on the
data of 2011. Further analysis of data from 2008 to 2012 suggests
that the incidence of malaria remain consistently low even if the
high risk population has not decreased significantly as compared
to countries like China and Brazil (Figure 2). It is possible that
people living in specific regions of high endemic zones of African
countries or Brazil might have the similar trends of malaria inci-
dence. It is known that immune responses against blood stage
infection are the major factor in providing protective response.
However, it is possible that the low incidence of Malaria among
endemic populations like in India could be due to the contribution
of the liver-stage immune responses generated among them. This
might be because of their unique diets playing an important role
in attenuating the parasite, a critical factor in generating liver-stage
specific response.
PROMOTING LIVER-STAGE IMMUNE RESPONSES BY
NATURALLY ATTENUATED PARASITE
Based on our understanding from various reports, it is possible
that many compounds derived from the herbs/spices could atten-
uate the parasite provoking immune responses to malaria. People,
especially those living in the continents of Asia and Africa consume
herbs and spices as part of their daily diet that have many medic-
inal effects; e.g., turmeric, garlic, and black pepper are consumed
daily by Indians in almost all food items (31–34). The compounds
from various sources listed in Table 3 are shown to act on blood
or liver stage parasite. It is possible that some of those compounds
help induce liver-stage specific immune responses.
Quinine, arabinogalactan, curcumin, piperine, ellagic acid,
quercetin, alkaloids, flavonoids, cinnamic acid derivatives, and
allicin to name a few compounds are known to have anti-malarial
activity, present in the diet. Many anti-malarial drugs target heme
polymerization, essential for parasite to complete its life cycle.
Quercetine (apples, oranges, lemons, onions, nuts, garlic, and
neem leaves) is known to act on the blood stage parasite by
preventing heme polymerization through sequestration of free
hemin by forming quercetin–hemin complex (e.g., against P. fal-
ciparum 3D7) (35). It has also shown to inhibit parasite growth
in a dose dependent manner by interfering in the permeability
pathways. Quinine (grapefruit, lime, pomegranate, and parsley)
also prevents heme polymerization as well as binds to the DNA
of parasite at schizont stage and blocks its reproduction (36,
37). Ellagic acid (strawberry, pomegranates and the best source,
red raspberry seeds/red Raspberries) has been shown to act on
mature trophozoite and young schizont of blood stage parasite
while inhibiting hemozoin formation (38, 39, 63). It has also been
shown that ellagic acid potentiates the activity of anti-malarial
drugs like chloroquine, mefloquine, artesunate, and atovaquone.
According to a curative test, the ED50 of ellagic acid for Plasmod-
ium vinckeipetteri was around 1 mg/kg/day by the intraperitoneal
route. Under the same conditions, artesunate, the most effective
semi-synthetic derivative of artemisinin, shows an inferior ED50 of
5 mg/kg/day. Several studies treating mice intra-peritoneally with
ellagic acid before parasite inoculation showed high-level reduc-
tion (between 79 and 93%) of parasitemia by day 6 post-infection
suggesting a prophylactic effect of ellagic acid (38, 39, 63).
Arabinogalactan (tomatoes, carrots, pears, coconut, leek, onion,
spinach, broccoli, avocado, eggplant, mango, apples, apricot,
banana, radish, turmeric, echinacea tea, and marshmallow root)
enhances monocytes production and also activates macrophages
that play an important role in phagocytosis of the parasite, thus
www.frontiersin.org March 2015 | Volume 6 | Article 125 | 3
Dalai et al. Liver-stage specific immunity in endemic populations
Table 2 | List of states of India with their population, malaria endemic population, malaria confirmed cases, percent population at high risk, and
percent incidence of malaria.
State (A) Population (B) Population at
high risk
(C) Population at high
risk (%), (B×100)/A
(D) Malaria confirmed
cases
(E) Incidence of malaria (%),
(D×100)/B
Mizoram 1, 091, 014 1, 091, 014 100 8861 0.81
Tripura 3, 671, 032 3, 671, 032 100 14, 417 0.39
Arunachal Pradesh 1, 382, 611 1, 257, 586 91 13, 950 1.11
Jharkhand 32, 966, 238 28, 791, 697 87 160, 653 0.56
Odisha 41, 947, 358 36, 494, 063 87 308, 968 0.85
Meghalaya 2, 964, 007 2, 139, 948 72 25, 143 1.18
India 1, 210, 569, 573 26, 63, 25, 306 22 1, 310, 656 0.49
FIGURE 2 | Malaria incidences based on WHO report analysis. The
data show the % of malaria cases (in China, Brazil, India, and
Madagascar) during 2006–2012 reported in World Malaria Report. India
and Madagascar have comparative high endemicity but varying
infectivity whereas China and Brazil having low endemicity but
proportionally higher infectivity.
lowering the parasite load, and presenting parasite antigens to
help potentiate the liver-stage specific T cell responses (40, 41).
Quinones (basil oil) inhibit the parasite development at sch-
izont stage by blocking its mitochondrial electron transport and
respiratory chain without affecting the host (42, 43).
Curcumin (turmeric) acts by damaging the parasite DNA and
altering the histone acetylation that accounts for the parasiticidal
activity on blood stage parasite (43–48). It has been shown that
curcumin inhibits chloroquine-resistant P. falciparum growth in a
dose dependent manner with an IC50 of 5µM (46). Furthermore,
oral administration of curcumin to mice infected with Plasmod-
ium berghei reduces blood parasitemia by 80–90% and enhances
the survival. Padmanaban et al. evaluated the in vivo efficacy of
the curcumin–artemisinin combination (46). The results indicated
that a, J3-arteether or curcumin monotherapy at the indicated
doses prolongs the survival of P. berghei-infected mice but does
not confer complete protection. However, combining curcumin
with a, J3-arteether treatment reduces the infectivity further result-
ing 100% protection. Consumption of black pepper, source of
piperine, is very common even among non-endemic populations.
Piperine has been shown to enhance the bioavailability of cur-
cumin by 2000-fold (33). The amount of curcumin consumed by
endemic population (e.g., India) appears to support the fact that it
would be enough to attenuate the parasite in the liver (34, 49–51).
Cinnamic acid (cinnamon) derivatives have been shown to act at
the young (ring) and the mature (trophozoite) stages of parasite
development by inhibition of lactate transport or of mitochondrial
respiration required for energy generation (52, 53, 64).
Allicin (garlic cloves) has been shown to prevent the para-
site invasion in hepatocytes, reduce parasite load in blood, and
enhance survival. It has been shown that the circumsporozoite pro-
tein (CSP) of Plasmodium sporozoites is proteolytically processed
by a parasite-derived cysteine protease, and this processing event
is associated with sporozoite invasion of host cells (54). It is
found that 10, 25, or 50µm allicin inhibit CSP cleavage, which
is comparable to that observed with 10µm E-64, a cysteine pro-
tease inhibitor that inhibits CSP processing and prevents inva-
sion of host cells in vitro and in vivo. Mice injected with allicin
showed reduced parasitemia compared to controls. Furthermore,
treatment of sporozoite with allicin before injecting into mice
completely prevented malaria infection suggesting allicin might
directly attenuate the parasite (55). The protective effect of allicin
seems to be influenced by improved host immune responses. It has
been demonstrated in a rodent malaria model of Plasmodium yoelli
(17XL) infection that allicin treatment enhances the production of
pro-inflammatory mediators like IFN-γ, TNF, IL-12p70, and NO.
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Table 3 |The compounds derived from various sources with their anti-malarial activity, mode of action and estimated concentration.
Fruits or herbs Compound present Estimated concentration Mode of action (anti-malarial activity) Reference
Apples, oranges,
lemons, onions, nuts,
garlic, neem leaves
Quercetine (flavonoid) 32 mg/100 g of red onion;
Daily intake 12.9 g/day)
Inhibition of heme polymerization by chelating free
available hemin for polymerization
(35)
Grapefruit, lime,
pomegranate, parsley
Quinine (alkaloids) ~100 mg total alkaloids,
including quinine in a cup
of traditional quinine bark
tea
Blocks malaria from reproducing by binding to the
parasite’s DNA
(36, 37)
Inhibition of hemozoin bio-crystallization, which facilitates
the aggregation of cytotoxic heme. Free cytotoxic heme
accumulates in the parasites, causing their deaths.
Strawberry,
pomegranates and the
best source, red
raspberry seeds/red
raspberries
Ellagic acid (polyphenol) 50.06 mg/10 gm of
strawberry
Inhibition of β-hematin (hemozoin) formation (38, 39)
Act on trophozoite and early schizont forms of the
parasites. This erythrocytic stage of the malaria life cycle
is the most metabolically active phase, with protein,
RNA, and DNA synthesis taking place.
Tomatoes, carrots,
pears, coconut, leek,
onion, spinach, broccoli,
avocado, eggplant,
mango, apples, apricot,
banana, radish,
turmeric, echinacea tea,
marshmallow root
Arabinogalactan
(polysaccharides)
15–25% in larch Macrophage activator
Support the monocyte production
(40, 41)
Basil oil Quinones N/A Inhibition of parasite mitochondrial electron transport
chain and respiratory chain without affecting the host
mitochondrial system
(42, 43)
Turmeric Curcumin (curcuminoid)
(natural phenols)
3.14% by weight in pure
turmeric powder; Alleppey
turmeric: 4–7% curcumin;
Madras type: 2% curcumin
Anti-oxidant activity (34, 44–51)
Curcumin induced generation of ROS may lead to
histone hypoacetylation and DNA damage that account
for the parasiticidal effect of curcumin
Black pepper Piperine 5–10% Enhances the bioavailability of curcumin by 2000-fold (33)
(Continued)
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Table 3 | Continued
Fruits or herbs Compound present Estimated concentration Mode of action (anti-malarial activity) Reference
Cinnamon Cinnamic acid
derivatives
0.96–2.91%; 0.87 mg/g Inhibit the transport of monocarboxylate across
erythrocyte and mitochondrial membranes
(52, 53)
Inhibit parasite growth and they are equally effective at
the young (ring) and the mature (trophozoite) stages of
parasite development
Garlic cloves Allicin, organosulfur
compound
1–3% (2.8–7.7 mg/g found
in Romanian red)
Inhibits circumsporozoite protein processing and
prevents sporozoite invasion of host cells in vitro. In vivo
mice injected with allicin had decreased Plasmodium
infections compared to controls
(54–56)
When sporozoites were treated with allicin before
injection into mice, malaria infection was completely
prevented
Immunomodulatory activities (preferentially enhances
pro-inflammatory immune responses)
Fenugreek In leaves: alkaloids,
saponin, tannin like
phenolic compounds,
flavonoids and steroids
Fenugreek contains 35%
alkaloids and 4.8% saponin
Hemozoin inhibitors (57, 58)
The alkaloidal, ethanol, and butanol extract of fenugreek
has been documented to possess anti-plasmodial activity
against in vitro culture of chloroquine sensitive and
resistant Plasmodium falciparum
Presence of flavonoids and polyphenols has been found
to be responsible for powerful anti-oxidant activity
Fenugreek seeds also have capacity to increase the
immunity power and to fight against the parasites
Peanuts, grapes, grape
juice, berries, e.g.,
blueberries and black
berries
Resveratrol (stilbenoid,
a type of natural phenol)
0.01–0.26 mg in peanuts Treatment of parasite-infected red blood cells with
resveratrol significantly reduces their ability to adhere to
the body’s cells lining small blood vessels. That reduction
in binding to blood vessels is predicted to greatly lessen
the probability of developing severe clinical
manifestations of malaria, according to the study.
(59)
Ginger N/A N/A Nausea and vomiting are also common symptoms of
malaria, which may explain the widespread use of ginger
as one component of traditional remedies for malaria
(60)
It stimulates production of the main anti-oxidant enzyme
glutathione peroxidase, this detoxification-related
enzyme improves the liver function and binds toxins. The
compounds of ginger inhibit the malaria parasite.
Cold-pressed coconut
oil, fresh and dried
coconut, coconut milk,
bitter melon
Lauric acid
(Saturated fatty acid)
ferulic acid and
p-coumaric acid
Pure coconut oil contains
about 50% lauric acid
When lauric acid is converted into monolaurin, a
monoglyceride compound, which exhibits antiviral,
antimicrobial, anti-protozoal, and anti-fungal properties. It
acts by disrupting the lipid membranes in organisms like
fungus, bacteria, and viruses, thus destroying them
Coconut has anti-oxidant compounds
(61, 62)
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The numbers of CD4+ T cells, DCs, and macrophages were sig-
nificantly higher in allicin-treated mice. Allicin also promoted the
maturation of CD11c+DCs, while it did not cause major changes
in IL-4 and the level of anti-inflammatory cytokine IL-10 (54–56).
Fenugreek is a common household item in special food prepa-
ration of Indians. Alkaloids and flavonoids derived from Fenu-
greek have been shown to inhibit the hemozoin formation and
possess anti-plasmodial activity against chloroquine sensitive and
resistant P. falciparum. It was found that fenugreek extract in a dose
of 50, 100, or 250 mg/kg showed immunomodulatory property
through various mechanisms including weight of thymus, delayed
type of hypersensitivity response, humoral immunity and phago-
cytosis (57, 58, 65, 66). Peanuts, grapes, grape juice, and berries are
common food consumed all over the world. Resveratrol, derived
from the same have been shown to significantly reduce the abil-
ity of infected RBCs to adhere to the body’s cells lining small
blood vessels. Such phenomenon is predicted to greatly lessen the
probability of developing severe clinical manifestations of malaria,
according to the study (59).
Frequent consumption or decoction of medicinal plants by
the people in malaria endemic areas has been shown to help
fight the infection. Evidence for this came from the longitudi-
nal study undertaken by Foundation for Revitalization of Local
Health Traditions (FRLHT) in endemic regions of Odisha, Andhra
Pradesh, and Chhattisgarh of India. It showed that traditional
plant decoction taken by people (tribal and non-tribal) reduced
the incidence of malaria by more than threefold (in communi-
cation, 67–69). Based on the actions of said compounds present
in diet and/or in decoction, it is possible that parasite develop-
ment is largely interrupted at the blood stage; in other words the
Plasmodia infection among endemic populations, as in case of
India, would preferentially be restricted to the liver stage help-
ing provoke immune response against the LSAs. Therefore, we
hypothesize that natural diet of people of different subcontinent
could attenuate Plasmodia at different stages of infection and thus
help provoke the immune responses against malaria liver-stage
infection enhancing protection (Figure 3). Recent findings from
the studies of vaccination of host using infectious sporozoite under
the cover of chloroquine support the hypothesis.
LESSONS FROM CHEMOPROPHYLAXIS STUDY WITH
CHLOROQUINE AND DETERMINING FACTORS FOR
PROTECTIVE IMMUNITY
In endemic areas, people are repeatedly exposed to malaria par-
asite and control the infection with immune responses directed
against the blood stage, as supported by majority of the investi-
gations (2), or with the help of anti-malarial drugs. It is possible
that interruption of parasite development at different stages, either
in liver or in blood, by natural means or drug usage favors gen-
eration of liver-stage specific immune responses (Figure 4) (70).
This possibility is revealed by the CPS immunization studies in
mice and humans. In CPS immunization, three doses of parasite
under chloroquine cover induce sterile protection that correlates
with CD8+ T cell responses directed against the pre-erythrocytic
stage of parasite (7, 8). In these studies, the immunized volunteers
have been shown to be protected for up to 2 years. Similarly, it is
FIGURE 3 | Proposed altered life cycle of Plasmodium following
consumption of diet containing anti-malarial compounds. Action of
various compounds derived from diet is depicted in the figure. Green
colored parasite represents normal life cycle while that of red colored
parasite represents defective life cycle because of action of compounds
present in diet. Possibilities: SPZ not able to infect the hepatocytes;
parasite development is interrupted at initial or late stage in hepatocytes; or
merozoites released might not able to infect the RBCs. Certain compounds
in diet might attenuate the parasite following infection in RBCs.
FIGURE 4 | Restricting the parasite development to Liver stage and
generation of immune responses. RTS,S vaccines targeting the
circumsporozoite protein (CSP) of the parasite generates mainly antibody
responses against the CSP that acts on the sporozoite to prevent its
invasion into hepatocytes. Allicin from the garlic cloves also would act in
similar manner (prevention of hepatocyte invasion by spz) by eliminating
CSP processing. After invading the hepatocyte sporozoite will undergo
further development, and merozoites released infect the RBCs and start
degrading Hb. Heme released is polymerized to curtail its toxicity on the
parasite. Chloroquine at this stage blocks the heme polymerization and kills
the parasite. Thus, chloroquine (or compounds from food having similar
action) would restrict the parasite development. Parasitic antigens released
from the infected RBCs might generate the humoral and cellular responses
to the blood stage parasite and also against the cross stage antigens from
liver stage parasite (69).
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possible that compounds from dietary plants, as described above
and medicinal decoction (during the diseased condition), would
have similar actions like to Chloroquine. In fact, the effective anti-
malarial drugs we use today are derived from the plants. In malaria
endemic areas, though maternal antibodies help fight the infec-
tion during their early life; children are highly prone to infection,
which might be due to their developing immune system. Their
susceptibility to malaria infection increases further probably for
the fact that consumption of herbs and spices as part of food is
quite low or rare in children, which increases as they grow. Hence,
with the advancement of age, repeated exposure to the parasite,
and frequent consumption of the herbs and spices might help
to develop the protective immunity against the malaria, which is
further supported by the observation that after several years of
exposure to parasite children do develop immunity to the severe
life threatening malaria (2).
Although blood stage specific immune responses seem to be
dominating protection, the presence of liver-stage specific immune
responses should not be underestimated. Possible reasons for not
having noticeable liver-stage immunity among endemic popu-
lation could be the low antigen availability and the tolerogenic
environment in liver that keeps the inflammation under con-
trol. Hence in case of malaria, the parasite load and its frequency
of exposure are the key factors to develop protective immunity
against liver-stage infection. In natural exposure, the parasite load
appears to be lower in endemic population compared to the
immunization regimen in experimental studies. However, there
is possibility of induction and building up of liver-stage specific
immune responses in endemic populations over the years of expo-
sures contributing to the protection (Figure 5). Many pre-clinical
vaccine studies including ours support the above notion (71–73).
In CPS immunization studies, it has been seen that three doses
of parasite (sporozoite) immunization under the cover of chloro-
quine through i.v. route within short time period induce the sterile
protection (26). While two doses of 20,000 sporozoite (spz) immu-
nization protect 40% of mice, three doses of the same protect 100%
of mice following infectious sporozoite challenge. Similar results
were also found in our experiments using attenuated parasite (γ-
spz) immunization strategy (manuscript in preparation, 71). The
higher level of protection correlates with the presence of higher
number of multifunctional CD8+ T cells suggesting that multiple
exposure to parasite antigens is required to achieve the protecting
numbers of multifunctional CD8+ T cells (74). It is also possible
that CD8+ T cell repertoire would be broadened for the subdom-
inant antigens (antigens from various stages of development in
liver) with repeated Ag exposure and ensue the protection against
liver-stage malaria. Interestingly, it has been demonstrated that
mice immunized with three doses of 10,000 spz under the cover of
chloroquine were partially protected in contrast to mice that were
given three doses of 20,000 spz (26). Further support came from
the comparative studies in which the immunizations of attenuated
parasites were done through intradermal (ID) vs. intravenous (IV)
routes. ID route of immunization was thought to mimic the nat-
ural route of delivery of sporozoite through mosquito bite. It was
FIGURE 5 | Generation of CD8T cell response vs. protection. CD8 T
cells are generated following exposure to parasite antigens through natural
infection. Depending on the availability and affinity of antigens CD8 T cell
clonotypes would have access to MHC/p complexes. Initially MHC/p in
excess or with high affinity would preferentially induce the specific T cells.
During subsequent antigen exposures other antigens would come into
picture while response to previously generated CD8 T cells will be
boosted. Gradually over time the desired repertoire of T cells with required
frequencies would be generated helping protect the host from the
incoming infection.
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found that immunization of mice through IV route was protective,
while the same through ID route failed to protect the mice upon
challenge (75). It has been demonstrated that parasite load in liver
in case of ID immunization is very low compared to the IV (75)
reflecting the low levels of the availability of antigens, which might
be not sufficient to induce the desired magnitude of CD8+ T cells
and to broaden the repertoire. To better understand the liver-stage
specific immune responses, protected individuals in endemic areas
should be included in large scale studies while CPS immunizations
in humans could be taken as alternative positive control. Screening
of protective antigens from those individuals will help the efforts
of subunit vaccination.
CONCLUSION
Over a decade ago, the malaria genome was sequenced, which has
revealed that the parasite contains over 5000 genes. Researchers
around the globe are actively engaged in identifying and char-
acterizing the genes. We have not yet been very successful in
making effective vaccines, which could generate the protective
immune responses against various developmental stages of Plas-
modia infection. It is well known that multiple immune mecha-
nisms are required to prevent the infection, e.g., CD8+ T cells are
critical for liver-stage infection as parasite remains inside the hepa-
tocytes while humoral response is the key mechanism in blood
stage infection where antibodies are required to prevent the free
merozoites to infect the RBCs (27). In addition, to prevent the
sporozoite from invading the hepatocytes, we require neutralizing
antibodies. Hence, a vaccine should be made, which could generate
a diverse immune response. RTS,S is the most successful subunit
vaccine available that produces the neutralizing antibodies against
the CSP, present on the surface of sporozoite. Currently, whole
sporozoite vaccines (RAS or GAS) are also becoming popular as
they confer the sterile protection at least in experimental models
by activating CD8+ T cells. Here, RAS are mainly restricted to ini-
tial stage while GAS are designed to be restricted at early, mid, or
late in liver-stage development. Interestingly, chemoprophylaxis
studies with chloroquine have shown the activation of both CD8+
T cells and antibody response in which parasite is prevented at
early blood stage (26).
Although we have understood mechanistically immune
responses generated in animals or in experimental trials in
humans, we have very little idea about the antigenic targets against
which immune responses seems to be protective. And this is
particularly true for liver-stage infection. Because there is lack
of understanding of induction of protective immune response
among endemic population against liver-stage infection, it has
been very difficult to identify the targets. Therefore, systemic
efforts must be made to understand liver-stage specific protec-
tive immune responses, particularly, in those populations living
in malaria endemic area who are protected from the malaria by
getting repeated exposure to the parasite. A recombinant pro-
tein of liver-stage parasite in adjuvant formulation will be an
ideal formulation for mass scale immunization. A pre-erythrocytic
stage vaccine should induce strong cellular immune response
as well as develop long lasting immunological memory. New
insight into parasite biology, stage specific expression profile, and
characterization of carefully selected new antigens would provide
new targets for interventions. Research institutes with focused
R&D and skilled manpower must take the lead in the efforts to
make vaccine against malaria by targeting antigens from multiple
stages of Plasmodia infection.
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